Highlights

Hartalega Holdings - A good end to FY18

Date: 16/05/2018

Source  :  AMMB
Stock  :  HARTA       Price Target  :  5.70      |      Price Call  :  HOLD
        Last Price  :  5.30      |      Upside/Downside  :  +0.40 (7.55%)
 


Investment Highlights

  • Hartalega’s foresight and execution hold it in good stead with its visible capacity expansion and its new product launch, against the backdrop of earnings delivery.
  • We maintain our HOLD recommendation with a DCF derived FV of RM5.70/share (WACC: 7.3% terminal growth: 2.5%). It implies a P/E of 32x CY19F. We believe elevated valuations are justified by Hartalega’s potential inclusion into the FBM KLCI, its leading glove producer position and high earnings visibility (3-year earnings CAGR FY18-FY21 of 15.6%).
  • Hartalega recorded a 4QFY18 profit of RM116.6mil (QoQ: +3%, YoY: +30%), bringing FY18 to RM439.4mil (YoY: +55%). It came broadly in line with consensus forecasts, at 103% of estimates.
  • Hartalega’s key highlights included: 1. Topline for the quarter grew 2.3% QoQ against volume growth, aided by the full commissioning of Plant 4 and robust volume demand. It was partially offset by marginally lower ASPs (QoQ: -1%) and the weaker USD/MYR (QoQ: -4%). 2. Hartalega’s newly developed gloves, anti-microbial gloves will be launched in Europe in May 2018. It will be priced competitively to gain better uptake. Therefore, we do not expect for it to be margin accretive. It would however, better insulate itself from an influx of homogenous glove supply going forward. 3. Plant 5’s (4bil or 13% of existing capacity) progressive commissioning from 1HCY18 onwards, to meet demand for its anti-microbial gloves. While capacity for Plant 5 has already been filled, it should marginally lower the plant’s elevated utilisation rate of 89%. 4. Operating margins came in lower by 1.1ppts QoQ for the quarter. Aside from lower ASPs, cost crept up, particularly fuel and labour cost.
  • We expect Hartalega’s robust growth to be driven by its capacity expansion in the midst of its new anti-microbial gloves, which they believe should be the new industry standard. Our USD/MYR sensitivity estimates earnings to be impacted by +5% for every +10% deviation from our FY19F assumption of MYR4.00/USD.
  • Key risks to Hartalega include capacity delays, a weaker MYR and a sharp appreciation in cost.

Source: AmInvest Research - 16 May 2018

Share this
Labels: HARTA

Related Stocks

Chart Stock Name Last Change Volume 
HARTA 5.30 +0.05 (0.95%) 12,923,500 

  Be the first to like this.
 


 

402  326  492  672 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 ARMADA 0.22+0.06 
 SAPNRG 0.285-0.005 
 SUMATEC 0.005-0.01 
 MYEG 1.01-0.06 
 BARAKAH 0.08+0.02 
 NEXGRAM 0.020.00 
 IRIS 0.15+0.005 
 XINGHE 0.045+0.005 
 KNM 0.09+0.01 
 ECONBHD 0.515+0.045 

TOP ARTICLES

1. 当遇上基本面投资法(上) “反向”战略非唱反调/冷眼 【冷眼专栏】漫漫投资路
2. Stocks on Radar - AirAsia Group (5099) AmInvest Research Reports
3. Stocks on Radar - Elsoft Research (0090) AmInvest Research Reports
4. FPI FY19 revenue growth expected to hit 15% FPI 2大因素前景看好台灣聯友今年再 尋突破
5. [转贴] 真实还原97亚洲金融风暴,韩国从暴富到破产仅用时7天! Good Articles to Share
6. JAKS Resources Berhad - RM25.5m P&L Hit PublicInvest Research
7. Fear on Bumi Armada is probably overdone - felicity Good Articles to Share
8. THE PERCEPTION OF P/E or: How I learned to fear my Wife the bursa journey that worked for me. 2000-2019
Partners & Brokers